Nirmatrelvir/Ritonavir Prescription Rate and Outcomes in Coronavirus Disease 2019: A Single Center Study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Nirmatrelvir/ritonavir was Korea's first oral antiviral agent to treat coronavirus disease 2019 (COVID-19). We analyzed the nirmatrelvir/ritonavir prescription rate and treatment outcomes in treatment-eligible patients with COVID-19 receiving home-based care. Materials and methods: We retrospectively collected data of patients with COVID-19-eligible for nirmatrelvir/ritonavir treatment from January 14, 2022, to February 15, 2022. We analyzed the prescription rate of nirmatrelvir/ritonavir, the reasons for non-prescription, and patient outcomes. Results: A total of 414 patients were included, of whom 44.2% were male, and the mean age was 64.6 (standard deviation [SD] = 8.5). Approximately 73.2% (n = 303) of patients were not prescribed nirmatrelvir/ritonavir. More than fourth-fifths of the patients refused nirmatrelvir/ritonavir treatment (n = 262, 86.5%). The mean symptom duration was significantly shorter in the prescription group (5.2 days [SD = 2.3] vs. 4.4 days [SD = 1.9], P = 0.001). A total of 6 (1.4%) patients were hospitalized, and none of the patients who received nirmatrelvir/ritonavir required admission. Among the patients prescribed nirmatrelvir/ritonavir (n = 111), 17 (15.3%) patients experienced side effects, and 5 (4.5%) patients discontinued nirmatrelvir/ritonavir due to side effects. Conclusion: The nirmatrelvir/ritonavir prescription rate was low, with more than fourth-fifths of non-prescriptions being due to patient refusal. Symptom resolution was faster, and no life-threatening side effects were reported. Accurate information about drug safety must be provided to patients to make informed decisions regarding nirmatrelvir/ritonavir treatment.
Abstract
Background: Nirmatrelvir/ritonavir was Korea's first oral antiviral agent to treat coronavirus disease 2019 (COVID-19). We analyzed the nirmatrelvir/ritonavir prescription rate and treatment outcomes in treatment-eligible patients with COVID-19 receiving home-based care. Materials and methods: We retrospectively collected data of patients with COVID-19-eligible for nirmatrelvir/ritonavir treatment from January 14, 2022, to February 15, 2022. We analyzed the prescription rate of nirmatrelvir/ritonavir, the reasons for non-prescription, and patient outcomes. Results: A total of 414 patients were included, of whom 44.2% were male, and the mean age was 64.6 (standard deviation [SD] = 8.5). Approximately 73.2% (n = 303) of patients were not prescribed nirmatrelvir/ritonavir. More than fourth-fifths of the patients refused nirmatrelvir/ritonavir treatment (n = 262, 86.5%). The mean symptom duration was significantly shorter in the prescription group (5.2 days [SD = 2.3] vs. 4.4 days [SD = 1.9], P = 0.001). A total of 6 (1.4%) patients were hospitalized, and none of the patients who received nirmatrelvir/ritonavir required admission. Among the patients prescribed nirmatrelvir/ritonavir (n = 111), 17 (15.3%) patients experienced side effects, and 5 (4.5%) patients discontinued nirmatrelvir/ritonavir due to side effects. Conclusion: The nirmatrelvir/ritonavir prescription rate was low, with more than fourth-fifths of non-prescriptions being due to patient refusal. Symptom resolution was faster, and no life-threatening side effects were reported. Accurate information about drug safety must be provided to patients to make informed decisions regarding nirmatrelvir/ritonavir treatment.
참고문헌 (21)
- "COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)"[URL]
- "Coronavirus (COVID-19) vaccinations"[URL]
- RECOVERY Collaborative Group, "Dexamethasone in hospitalized patients with Covid-19", N Engl J Med, 384, pp.693~704 (2021)
- Jayk Bernal A, "Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients", N Engl J Med, 386, pp.509~520 (2022)
- Abbass S, "Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19 : A randomized controlled trial", J Med Virol, 93, pp.6750~6759 (2021)
- Beigel JH, "Remdesivir for the treatment of Covid-19-final report", N Engl J Med, 383, pp.1813~1826 (2020)
- Hammond J, "Oral nirmatrelvir for highrisk, nonhospitalized adults with Covid-19", N Engl J Med, 386, pp.1397~1408 (2022)
- Hong Sun In, "Real World Experience with Regdanvimab Treatment of Mild-to-Moderate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea", Infection and Chemotherapy, 54(1), pp.114~124 (2022), 대한감염학회[DOI]
- "Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19"[URL]
- Hsu A, "Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents", Clin Pharmacokinet, 35, pp.275~291 (1998)
- "Emergency use approval of “Paxlovid”, an oral COVID-19 treatment"[URL]
- "COVID-19 treatment guideline 4th edition"[URL]
- "COVID-19 treatment guideline 4. 2nd ed"[URL]
- "COVID-19 treatment guidelines. Ritonavir-boosted nirmatrelvir (Paxlovid)"[URL]
- Razzack Aminah Abdul, "A Meta-Analysis of Association between Remdesivir and Mortality among Critically-Ill COVID-19 Patients", Infection and Chemotherapy, 53(3), pp.512~518 (2021), 대한감염학회[DOI]
- Hong Kyung Soo, "Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication", Infection and Chemotherapy, 52(3), pp.396~402 (2020), 대한감염학회[DOI]
- Kim Sun Bean, "Interim Guidelines on Antiviral Therapy for COVID-19", Infection and Chemotherapy, 52(2), pp.281~304 (2020), 대한감염학회[DOI]
- Kim Sun Bean, "Revised Korean Society of Infectious Diseases", National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19, 2021, pp.53(1), 166~219[DOI]
- Meo SA, "Omicron SARS-CoV-2 new variant : global prevalence and biological and clinical characteristics", Eur Rev Med Pharmacol Sci, 25, pp.8012~8018 (2021)
- "COVID-19 drug interaction"[URL]
- "Investigation results of early administration of oral antiviral agents"[URL]